Brief: Ascelia Pharma Suspends Clinical Activities In Russia

Ascelia Pharma AB

08/03/2022 06:23

March 8 (Reuters) - Ascelia Pharma AB  ACELP.ST :
    * SAID ON MONDAY SUSPENDS CLINICAL ACTIVITIES IN RUSSIA
    * DUE TO THE RUSSIAN INVASION OF UKRAINE, ALL CLINICAL
ACTIVITIES
IN RUSSIA IN THE ONGOING PHASE 3 STUDY SPARKLE ARE BEING
SUSPENDED
    * AS A CONSEQUENCE, THE EXPECTED RECRUITMENT COMPLETION FOR
THE
SPARKLE STUDY IS EXTENDED TO 2022 (PREVIOUSLY H1 2022)
    * AS PREVIOUSLY COMMUNICATED, ASCELIA PHARMA HAS SUFFICIENT
FINANCING TO COMPLETE THE SPARKLE STUDY

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN8VmPbB
 Further company coverage:  ACELP.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))